Cargando…
Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives
Monoclonal antibodies have been the most successful therapeutics ever brought to cancer treatment by immune technologies. The use of monoclonal antibodies in B-cell Non-Hodgkin's lymphomas (NHL) represents the greatest example of these advances, as the introduction of the anti-CD20 antibody rit...
Autores principales: | Motta, Giulia, Cea, Michele, Moran, Eva, Carbone, Federico, Augusti, Valeria, Patrone, Franco, Nencioni, Alessio |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3061293/ https://www.ncbi.nlm.nih.gov/pubmed/21437222 http://dx.doi.org/10.1155/2010/428253 |
Ejemplares similares
-
Grb7 Upregulation Is a Molecular Adaptation to HER2 Signaling Inhibition Due to Removal of Akt-Mediated Gene Repression
por: Nencioni, Alessio, et al.
Publicado: (2010) -
Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2023) -
Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice
por: Tavarozzi, Rita, et al.
Publicado: (2023) -
Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
por: Bobrowicz, Malgorzata, et al.
Publicado: (2019) -
Progressive Encephalomyelitis with Rigidity and Myoclonus Associated With Anti-GlyR Antibodies and Hodgkin’s Lymphoma: A Case Report
por: Borellini, Linda, et al.
Publicado: (2017)